278 related articles for article (PubMed ID: 23398532)
1. TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.
Givvimani S; Kundu S; Narayanan N; Armaghan F; Qipshidze N; Pushpakumar S; Vacek TP; Tyagi SC
Arch Physiol Biochem; 2013 May; 119(2):65-74. PubMed ID: 23398532
[TBL] [Abstract][Full Text] [Related]
2. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.
Givvimani S; Tyagi N; Sen U; Mishra PK; Qipshidze N; Munjal C; Vacek JC; Abe OA; Tyagi SC
Arch Physiol Biochem; 2010 May; 116(2):63-72. PubMed ID: 20230216
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure.
Givvimani S; Munjal C; Tyagi N; Sen U; Metreveli N; Tyagi SC
PLoS One; 2012; 7(3):e32388. PubMed ID: 22479323
[TBL] [Abstract][Full Text] [Related]
4. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.
Kassiri Z; Oudit GY; Sanchez O; Dawood F; Mohammed FF; Nuttall RK; Edwards DR; Liu PP; Backx PH; Khokha R
Circ Res; 2005 Aug; 97(4):380-90. PubMed ID: 16037568
[TBL] [Abstract][Full Text] [Related]
5. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
6. Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure.
Givvimani S; Munjal C; Gargoum R; Sen U; Tyagi N; Vacek JC; Tyagi SC
J Appl Physiol (1985); 2011 Apr; 110(4):1093-100. PubMed ID: 21233344
[TBL] [Abstract][Full Text] [Related]
7. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis.
Friehs I; Margossian RE; Moran AM; Cao-Danh H; Moses MA; del Nido PJ
Basic Res Cardiol; 2006 May; 101(3):204-13. PubMed ID: 16369727
[TBL] [Abstract][Full Text] [Related]
9. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload.
Matsusaka H; Ide T; Matsushima S; Ikeuchi M; Kubota T; Sunagawa K; Kinugawa S; Tsutsui H
Hypertension; 2006 Apr; 47(4):711-7. PubMed ID: 16505197
[TBL] [Abstract][Full Text] [Related]
10. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.
Voloshenyuk TG; Gardner JD
Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R683-93. PubMed ID: 20504902
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
12. Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model.
Foronjy RF; Sun J; Lemaitre V; D'Armiento JM
Hypertens Res; 2008 Apr; 31(4):725-35. PubMed ID: 18633185
[TBL] [Abstract][Full Text] [Related]
13. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.
Heymans S; Lupu F; Terclavers S; Vanwetswinkel B; Herbert JM; Baker A; Collen D; Carmeliet P; Moons L
Am J Pathol; 2005 Jan; 166(1):15-25. PubMed ID: 15631996
[TBL] [Abstract][Full Text] [Related]
14. Anti-Parstatin Promotes Angiogenesis and Ameliorates Left Ventricular Dysfunction during Pressure Overload.
Givvimani S; Narayanan N; Pushpakumar SB; C Tyagi S
Int J Biomed Sci; 2014 Mar; 10(1):1-7. PubMed ID: 24711742
[TBL] [Abstract][Full Text] [Related]
15. Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction.
Jia ZB; Tian H; Kang K; Miao HZ; Liu KY; Jiang SL; Wang LP
Transpl Immunol; 2014 May; 30(4):149-58. PubMed ID: 24727088
[TBL] [Abstract][Full Text] [Related]
16. Reverse remodeling is associated with changes in extracellular matrix proteases and tissue inhibitors after mesenchymal stem cell (MSC) treatment of pressure overload hypertrophy.
Molina EJ; Palma J; Gupta D; Torres D; Gaughan JP; Houser S; Macha M
J Tissue Eng Regen Med; 2009 Feb; 3(2):85-91. PubMed ID: 19065545
[TBL] [Abstract][Full Text] [Related]
17. Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.
Szabó Z; Magga J; Alakoski T; Ulvila J; Piuhola J; Vainio L; Kivirikko KI; Vuolteenaho O; Ruskoaho H; Lipson KE; Signore P; Kerkelä R
Hypertension; 2014 Jun; 63(6):1235-40. PubMed ID: 24688123
[TBL] [Abstract][Full Text] [Related]
18. Role of copper and homocysteine in pressure overload heart failure.
Hughes WM; Rodriguez WE; Rosenberger D; Chen J; Sen U; Tyagi N; Moshal KS; Vacek T; Kang YJ; Tyagi SC
Cardiovasc Toxicol; 2008; 8(3):137-44. PubMed ID: 18679830
[TBL] [Abstract][Full Text] [Related]
19. Oxidative remodeling in pressure overload induced chronic heart failure.
Henderson BC; Tyagi N; Ovechkin A; Kartha GK; Moshal KS; Tyagi SC
Eur J Heart Fail; 2007 May; 9(5):450-7. PubMed ID: 17306621
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.
Shimano M; Ouchi N; Shibata R; Ohashi K; Pimentel DR; Murohara T; Walsh K
J Mol Cell Cardiol; 2010 Aug; 49(2):210-20. PubMed ID: 20206634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
